Evidence map›Paper›PMID 28993504›Full record

ReviewJournal of the American Society of Nephrology : JASN2018

Precision Transplant Medicine: Biomarkers to the Rescue.

Maarten Naesens, Dany Anglicheau

Registry-linked trialAbstract readReview
In one paragraph

Review in Journal of the American Society of Nephrology : JASN, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05335538 (The Role of TruGraf® to Optimize Outcomes in Pediatric Renal Transplantation), which is not on this map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05335538 unknown statusnot on this mapstarted 2021, after this paper: background citation

The Role of TruGraf® to Optimize Outcomes in Pediatric Renal Transplantation

TypeobservationalSponsorTransplant Genomics, Inc.Ran2021 to 2023Enrolled75ConditionsKidney Transplant RejectionArmsPatients monitored with TruGraf and TRAC testing
3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Observational
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. The obese transplant organ recipient: experimental and clinical evidence for tailored immunosuppression.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Review
  13. Detection of Kidney Allograft Rejection Using Urinary Chemokines.Journal of the American Society of Nephrology : JASN · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Maarten NaesensDepartment of Microbiology and Immunology, Laboratory of Nephrology, Katholieke Universiteit Leuven, University of Leuven, Leuven, Belgium.
Dany AnglicheauNecker-Enfants Malades Institute, French National Institutes of Health and Medical Research U1151, Paris, France; dany.anglicheau@aphp.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The concept that individuals with the same disease and a similar clinical presentation may have very different outcomes and need very different therapies is not novel. With the development of many innovative tools derived from the omics technologies, transplant medicine is slowly entering the era of precision medicine. Biomarkers are the cornerstone of precision medicine, which aims to integrate biomarkers with traditional clinical information and tailor medical care to achieve the best outcome for an individual patient. Here, we discuss the basic concepts of precision medicine and biomarkers, with a specific focus on progress in renal transplantation. We delineate the different types of biomarkers and provide a general assessment of the current applications and shortcomings of previously proposed biomarkers. We also outline the potential of precision medicine in transplantation. Moving toward precision medicine in the field of transplantation will require transplant physicians to embrace the increased complexity and expanded decision algorithms and therapeutic options that are associated with improved disease nosology.

Indexed as

HLA AntigensKidney TransplantationPrecision MedicineBiomarkersHumansKidney DiseasesPatient SelectionPrognosisRisk AssessmentRNA, MessengerTissue DonorsBiomarkersHLA AntigensRNA, Messengeracute rejectionchronic allograft failurechronic graft deteriorationkidney transplantationtransplant outcomes

Identifiers

PMID28993504
PMCPMC5748900

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.